Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

New ICH draft guidance says a fed study is not necessary for most immediate-release solid oral dosage products and the FDA indicates it will consider revising product-specific guidances to harmonize standards.

fasting
New ICH draft guidance states only fasting studies should be required for most immediate-release solid oral dosage form generics to show bioequivalence. • Source: Shutterstock

Opinions inside the US Food and Drug Administration on requiring fed studies in generic drug development may be softening.

New International Council for Harmonisation (ICH) guidance could eventually push the agency to mandate only fasting studies for most immediate-release...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

US FDA’s ANDA Prioritization Pilot Encouraging Production Onshoring

 
• By 

The latest incentive for firms to move manufacturing to the US is an FDA pilot program that will prioritize the review of US-manufactured and tested ANDA products.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By 

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

US FDA Gives Leucovorin Unprecedented Path To New Claim Amid ‘Autism Crisis’

 

The Trump Administration's autism campaign convinced GSK to submit an sNDA for its no-longer-marketed leucovorin as a treatment for a rare folate deficiency condition with promises to ensure insurance coverage for autism.

Swissmedic Slashes Months Off Review Time For Certain Drug Filings

 

Switzerland’s health care products agency said it had cut the time it takes to review marketing applications for certain drugs submitted via its regulatory reliance procedure because it wants to further enhance the appeal of the pathway.

More from Biosimilars & Generics

How Will Trump’s Visa Brick, Rubio’s Tariff Fix, Lower Domestic Tax Impact Indian Pharma?

 
• By 

As US Secretary of State Marco Rubio hints at reconsideration of a punitive Russian oil tariff, Trump adds an H-1B visa brick to his trade wall and India lowers GST on cancer and rare disease drugs, the Pink Sheet considers the impact.

US FDA Gives Leucovorin Unprecedented Path To New Claim Amid ‘Autism Crisis’

 

The Trump Administration's autism campaign convinced GSK to submit an sNDA for its no-longer-marketed leucovorin as a treatment for a rare folate deficiency condition with promises to ensure insurance coverage for autism.

Korea’s New Health Minister: ‘Golden Time For The Country To Become A Biopharma Leader’

 
• By 

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse.